Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.

PloS one - 1 Jan 2011

Normanno Nicola, Pinto Carmine, Castiglione Francesca, Bardelli Alberto, Gambacorta Marcello, Botti Gerardo, Nappi Oscar, Siena Salvatore, Ciardiello Fortunato, Taddei Gianluigi, Marchetti Antonio

Abstract excerpt

BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate therapy for these patients. METHODOLOGY/PRINCIPAL FINDINGS: In order to guarantee the possibility for mCRC patients to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Mutation

Share to Polymerase Chain Reaction

Share to Practice Guidelines as Topic

Share to Quality Control

Source

Open in PubMed Open full text

Identifiers

PMID: 22216189
DOI: 10.1371/journal.pone.0029146
PMCID: PMC3244430

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.PMID 22216189Read ↗

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.Semantic proximity Read ↗

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.Semantic proximity Read ↗

Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.Semantic proximity Read ↗

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerSemantic proximity Read ↗

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide ExperienceSemantic proximity Read ↗

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.Semantic proximity Read ↗

[Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].Semantic proximity Read ↗

KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.Semantic proximity Read ↗

Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer.Semantic proximity Read ↗

[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.